Prognostic role of bone erosion in orbital RMS: a report from the European Pediatric Soft Tissue Sarcoma Study Group (EpSSG)

被引:0
作者
Di Carlo, Daniela [1 ,2 ]
Fichera, Giulia [3 ]
Minard-Colin, Veronique [4 ]
Coppadoro, Beatrice [5 ]
Orbach, Daniel [6 ]
Cameron, Alison [7 ,8 ]
Albiac Ramos, Monica [9 ]
Ben Arush, Myriam [10 ]
Merks, Johannes H. M. [11 ,12 ]
Bisogno, Gianni [1 ,2 ]
机构
[1] Univ Hosp Padova, Dept Womens & Childrens Hlth, Padua, Italy
[2] Univ Hosp Padova, Div Pediat Hematol Oncol, Padua, Italy
[3] Univ Hosp Padova, Pediat Radiol Unit, Padua, Italy
[4] Univ Paris Saclay, Inst Natl Sante & Rech Med, Gustave Roussy, INSERM,U1015,Gustave Roussy, Villejuif, France
[5] Padova Univ Hosp, Dept Womens & Childrens Hlth, Div Hematol Oncol, I-35128 Padua, Italy
[6] Pitie Salpetriere PSL Univ, Oncol Ctr Care Innovat & Res Children Adolescents, Soins Innovat Rech Oncol Enfant Adolescent & Adult, Inst Curie, Paris, France
[7] Univ Hosp Bristol & Weston NHS Fdn Trust, FRCR Bristol Haematol & Oncol Ctr, Bristol, England
[8] Weston NHS Fdn Trust, Bristol, England
[9] Hosp Valle De Hebron, Dept Radiat Oncol, Barcelona, Spain
[10] Ruth Rappaport Childrens Hosp, Joan & Sanford Weill Pediat Hematol Oncol & Bone, Haifa, Israel
[11] Princess Maxima Ctr Pediat Oncol, Utrecht, Netherlands
[12] Univ Utrecht, Univ Med Ctr Utrecht, Div Imaging & Oncol, Utrecht, Netherlands
关键词
orbital tumor; parameningeal; bone erosion; pediatric rhabdomyosarcoma; RMS; RHABDOMYOSARCOMA; CHILDREN; ADOLESCENTS; HEAD;
D O I
10.3389/fonc.2024.1497193
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background: Orbital rhabdomyosarcoma (RMS) is often limited to the orbital cavity and has a favorable prognosis. In some cases, the tumor can erode the orbital bone and behave as a parameningeal RMS (PM-RMS); thus, it is treated more intensively. However, the current protocols do not provide any guidance on how to consider different grades of bone erosion (BE) that can vary widely, hampering a uniform classification and the subsequent treatment assignment. With the aim of clarifying the role of BE as a risk factor, we analyzed patients with orbital RMS included in the European Pediatric Soft Tissue Sarcoma Study Group (EpSSG) protocol. Methods: We retrospectively analyzed the radiological reports of 199 patients with orbital RMS (PM or not) and defined three grades of BE: minimal (thinning of the bone), moderate (focal bone lysis), and extensive (complete cortical destruction). Results: BE was present in 55 of the 199 (27.6%) patients, which was classified as minimal in 27, moderate in 7, and extensive in 21. Tumors with extensive BE were more frequently large (>5 cm, p = 0.0008) and invasive (T2, p = 0.001). With a median follow-up of 70.4 months (range = 7.1-167.7), a total of 183 patients are alive, with 5-year event-free survival (EFS) and overall survival (OS) rates of 76% (95%CI = 69.2-81.3) and 92% (95%CI = 86.7-94.8), respectively. Patients without any BE had better OS (95% vs. 81%, p = 0.001), but not EFS. Patients with no/minimal/moderate BE had better EFS and OS compared with patients with extensive BE [EFS of 78.1 (95%CI = 71.1-83.5) vs. 57.1 (95%CI = 33.8-74.9), p = 0.0114, respectively, and OS of 94.0 (95%CI = 89.2-96.8) vs. 71.1 (95%CI = 46.6-85.9), p < 0.0001, respectively]. Events and metastatic relapses (in all cases CNS/meningeal) were more frequent in patients with extensive BE. Conclusions: Only those patients with orbital RMS and extensive BE should be considered as PM and should be treated accordingly.
引用
收藏
页数:9
相关论文
共 20 条
[1]   Embryonal rhabdomyosarcoma completely resected at diagnosis: The European paediatric Soft tissue sarcoma Study Group RMS2005 experience [J].
Bergeron, Christophe ;
Jenney, Meriel ;
De Corti, Federica ;
Gallego, Soledad ;
Merks, Hans ;
Glosli, Heidi ;
Ferrari, Andrea ;
Ranchere-Vince, Dominique ;
De Salvo, Gian Luca ;
Zanetti, Ilaria ;
Chisholm, Julia ;
Minard-Colin, Veronique ;
Rogers, Timothy ;
Bisogno, Gianni .
EUROPEAN JOURNAL OF CANCER, 2021, 146 :21-29
[2]   Nonmetastatic Rhabdomyosarcoma in Children and Adolescents: Overall Results of the European Pediatric Soft Tissue Sarcoma Study Group RMS2005 Study [J].
Bisogno, Gianni ;
Minard-Colin, Veronique ;
Zanetti, Ilaria ;
Ferrari, Andrea ;
Gallego, Soledad ;
Fajardo, Raquel Davila ;
Mandeville, Henry ;
Kelsey, Anna ;
Alaggio, Rita ;
Orbach, Daniel ;
van Scheltinga, Sheila Terwisscha ;
Guillen Burrieza, Gabriela ;
Ben-Arush, Myriam ;
Glosli, Heidi ;
Mudry, Peter ;
Ferman, Sima ;
Devalck, Christine ;
Defachelles, Anne Sophie ;
Merks, Johannes Hendrikus Maria ;
Jenney, Meriel .
JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (13) :2342-2349
[3]   Vinorelbine and continuous low-dose cyclophosphamide as maintenance chemotherapy in patients with high-risk rhabdomyosarcoma (RMS 2005): a multicentre, open-label, randomised, phase 3 trial [J].
Bisogno, Gianni ;
De Salvo, Gian Luca ;
Bergeron, Christophe ;
Gallego Melcon, Soledad ;
Merks, Johannes H. ;
Kelsey, Anna ;
Martelli, Helene ;
Minard-Colin, Veronique ;
Orbach, Daniel ;
Glosli, Heidi ;
Chisholm, Julia ;
Casanova, Michela ;
Zanetti, Ilaria ;
Devalck, Christine ;
Ben-Arush, Myriam ;
Mudry, Peter ;
Ferman, Sima ;
Jenney, Meriel ;
Ferrari, Andrea .
LANCET ONCOLOGY, 2019, 20 (11) :1566-1575
[4]   Addition of dose-intensified doxorubicin to standard chemotherapy for rhabdomyosarcoma (EpSSG RMS 2005): a multicentre, open-label, randomised controlled, phase 3 trial [J].
Bisogno, Gianni ;
Jenney, Meriel ;
Bergeron, Christophe ;
Gallego Melcon, Soledad ;
Ferrari, Andrea ;
Oberlin, Odile ;
Carli, Modesto ;
Stevens, Michael ;
Kelsey, Anna ;
De Paoli, Angela ;
Gaze, Mark N. ;
Martelli, Helene ;
Devalck, Christine ;
Merks, Johannes H. ;
Ben-Arush, Myriam ;
Glosli, Heidi ;
Chisholm, Julia ;
Orbach, Daniel ;
Minard-Colin, Veronique ;
De Salvo, Gian Luca .
LANCET ONCOLOGY, 2018, 19 (08) :1061-1071
[5]  
Boutroux H, 2014, J PEDIAT HEMATOL ONC, V36, P605, DOI 10.1097/MPH.0000000000000245
[6]   Disease Control and Patterns of Failure After Proton Beam Therapy for Rhabdomyosarcoma [J].
Buszek, Samantha M. ;
Ludmir, Ethan B. ;
Grosshans, David R. ;
McAleer, Mary Frances ;
McGovern, Susan L. ;
Harrison, Douglas J. ;
Okcu, M. Fatih ;
Chintagumpala, Murali M. ;
Mahajan, Anita ;
Paulino, Arnold C. .
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2021, 109 (03) :718-725
[7]   Pediatric head and neck rhabdomyosarcoma: An analysis of treatment and survival in the United States (1975-2016) [J].
Darwish, Christina ;
Shim, Timothy ;
Sparks, Andrew D. ;
Chillakuru, Yeshwant ;
Strum, David ;
Benito, Daniel A. ;
Monfared, Ashkan .
INTERNATIONAL JOURNAL OF PEDIATRIC OTORHINOLARYNGOLOGY, 2020, 139
[8]  
De Salvo GL., 2024, Cancer, DOI [10.1002/cncr.v130.13, DOI 10.1002/CNCR.V130.13]
[9]  
Forstner D, 2006, Australas Radiol, V50, P41, DOI 10.1111/j.1440-1673.2005.01526.x
[10]   Non-parameningeal head and neck rhabdomyosarcoma in children, adolescents, and young adults: Experience of the European paediatric Soft tissue sarcoma Study Group (EpSSG)-RMS2005 study [J].
Glosli, Heidi ;
Bisogno, Gianni ;
Kelsey, Anna ;
Chisholm, Julia C. ;
Gaze, Mark ;
Kolb, Frederic ;
McHugh, Kieran ;
Shipley, Janet ;
Gallego, Soledad ;
Merks, Johannes H. M. ;
Smeele, Ludi E. ;
Mandeville, Henry ;
Ferrari, Andrea ;
Minard-Colin, Veronique ;
Corradini, Nadege ;
Jenney, Meriel ;
Zanetti, Ilaria ;
De Salvo, Gian L. ;
Orbach, Daniel .
EUROPEAN JOURNAL OF CANCER, 2021, 151 :84-93